Q-omics provides the consensus-scored PRAME profile across patient tissues and cancer cell-line models. PRAME expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRAME is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, PRAME RNA expression shows 15,218 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where PRAME shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAME — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAME survival associations across molecular data types. PRAME RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAME RNA expression–survival associations across cancer types. High PRAME expression shows unfavorable associations in UVM, ACC, KIRC, LUAD, BRCA and COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PRAME RNA expression.
This table summarizes PRAME tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PRAME. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAME shows higher tumor expression in KIRC, HNSC, LUSC, UCEC, LUAD and KIRP. The KIRC box plot shows higher PRAME RNA expression in tumor versus normal tissue (log2 FC = +2.192, t-test p < 0.001).
This table shows molecular features associated with PRAME in patient tissues and cancer cell lines. In patient samples, PRAME shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAME RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
